• Je něco špatně v tomto záznamu ?

Second primary malignancies in colorectal cancer patients

J. Halamkova, T. Kazda, L. Pehalova, R. Gonec, S. Kozakova, L. Bohovicova, DA. Krakorova, O. Slaby, R. Demlova, M. Svoboda, I. Kiss

. 2021 ; 11 (1) : 2759. [pub] 20210202

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004632

The prevalence of second primary malignancies (SPMs) in the western world is continually increasing with the risk of a new primary cancer in patients with previously diagnosed carcinoma at about 20%. The aim of this retrospective analysis is to identify SPMs in colorectal cancer patients in a single-institution cohort, describe the most frequent SPMs in colorectal cancer patients, and discover the time period to occurrence of second primary tumors. We identified 1174 patients diagnosed with colorectal cancer in the period 2003-2013, with follow-up till 31.12.2018, and median follow-up of 10.1 years, (median age 63 years, 724 men). A second primary neoplasm was diagnosed in 234 patients (19.9%). Older age patients, those with early-stage disease and those with no relapse have a higher risk of secondary cancer development. The median time from cancer diagnosis to development of CRC was 8.9 years for breast cancer and 3.4 years for prostate cancer. For the most common cancer diagnosis after primary CRC, the median time to development was 0-5.2 years, depending on the type of malignancy. Patients with a diagnosis of breast, prostate, or kidney cancer, or melanoma should be regularly screened for CRC. CRC patients should also be screened for additional CRC as well as cancers of the breast, prostate, kidney, and bladder. The screening of cancer patients for the most frequent malignancies along with systematic patient education in this field should be the standard of surveillance for colorectal cancer patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004632
003      
CZ-PrNML
005      
20240206090826.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-021-82248-7 $2 doi
035    __
$a (PubMed)33531585
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Halamkova, Jana $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Department of Medical Ethics, Faculty of Medicine, Masaryk University, Brno, Czech Republic
245    10
$a Second primary malignancies in colorectal cancer patients / $c J. Halamkova, T. Kazda, L. Pehalova, R. Gonec, S. Kozakova, L. Bohovicova, DA. Krakorova, O. Slaby, R. Demlova, M. Svoboda, I. Kiss
520    9_
$a The prevalence of second primary malignancies (SPMs) in the western world is continually increasing with the risk of a new primary cancer in patients with previously diagnosed carcinoma at about 20%. The aim of this retrospective analysis is to identify SPMs in colorectal cancer patients in a single-institution cohort, describe the most frequent SPMs in colorectal cancer patients, and discover the time period to occurrence of second primary tumors. We identified 1174 patients diagnosed with colorectal cancer in the period 2003-2013, with follow-up till 31.12.2018, and median follow-up of 10.1 years, (median age 63 years, 724 men). A second primary neoplasm was diagnosed in 234 patients (19.9%). Older age patients, those with early-stage disease and those with no relapse have a higher risk of secondary cancer development. The median time from cancer diagnosis to development of CRC was 8.9 years for breast cancer and 3.4 years for prostate cancer. For the most common cancer diagnosis after primary CRC, the median time to development was 0-5.2 years, depending on the type of malignancy. Patients with a diagnosis of breast, prostate, or kidney cancer, or melanoma should be regularly screened for CRC. CRC patients should also be screened for additional CRC as well as cancers of the breast, prostate, kidney, and bladder. The screening of cancer patients for the most frequent malignancies along with systematic patient education in this field should be the standard of surveillance for colorectal cancer patients.
650    _2
$a dospělí $7 D000328
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a přežívající onkologičtí pacienti $x statistika a číselné údaje $7 D000073116
650    _2
$a kolorektální nádory $x diagnóza $x mortalita $x terapie $7 D015179
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a sekundární malignity $x diagnóza $x epidemiologie $7 D016609
650    _2
$a vzdělávání pacientů jako téma $7 D010353
650    _2
$a prevalence $7 D015995
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a rizikové faktory $7 D012307
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kazda, Tomas $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Zluty kopec 7, Brno, 625 00, Czech Republic. tomas.kazda@mou.cz $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic. tomas.kazda@mou.cz
700    1_
$a Pehalova, Lucie $u Institute of Health Information and Statistics of the Czech Republic, Prague, Czech Republic $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Gonec, Roman $u Department of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Pharmaceutics, Faculty of Pharmacy, Masaryk University, Brno, Czech Republic
700    1_
$a Kozakova, Sarka $u Department of Pharmacy, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Bohovicova, Lucia $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Adámková Krákorová, Dagmar $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $7 xx0084127
700    1_
$a Slaby, Ondrej $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Central European Institute of Technology, Brno, Czech Republic
700    1_
$a Demlova, Regina $u Department of Pharmacology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $u Clinical Trial Unit, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Svoboda, Marek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Kiss, Igor $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic $u Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, Brno, Czech Republic
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 11, č. 1 (2021), s. 2759
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33531585 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20240206090823 $b ABA008
999    __
$a ok $b bmc $g 1751941 $s 1155781
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 11 $c 1 $d 2759 $e 20210202 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace